Charges of kidney stones are on the rise in the US and around the globe. Sort 2 diabetes is related to elevated danger of kidney stones, however some types of therapy for this situation can also take pleasure in decreasing danger of kidney stones.
In a examine led by investigators from Mass Common Brigham, researchers discovered that there was an affiliation between using sodium-glucose contratransporter 2 (SGLT2) inhibitors and a decrease danger of creating kidney stones. Their findings are reported in JAMA Inner Medication.
Researchers from Brigham and Ladies’s Hospital and Massachusetts Common Hospital labored collectively to conduct the evaluation. The examine included information from three nationwide databases of sufferers with sort 2 diabetes who have been seen in routine scientific follow. The crew analyzed info from 716,406 adults with sort 2 diabetes who had began taking an SGLT2 inhibitor or two different lessons of diabetes drugs generally known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
Sufferers who started taking SGLT2 inhibitors had a 30% decrease danger of creating kidney stones than these taking GLP1 agonists and a few 25% decrease danger than these taking DPP4 inhibitors. The findings have been constant throughout intercourse, race/ethnicity, historical past of power kidney illness and weight problems.
“Our findings might assist inform scientific choice making for sufferers with diabetes who’re in danger for creating kidney stones,” stated corresponding creator Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medication at Brigham and Ladies’s Hospital.
Extra Mass Common Brigham authors embody Helen Tesfaye (BWH) Gary C. Curhan (BWH), Heidi Zakoul (BWH), Deborah J. Wexler (MGH) and Elisabetta Patorno (BWH).
